
    
      The study is designed to evaluate the safety and effects of ATH-1017 in subjects with
      Parkinson's Disease Dementia, with a randomized, double-blind, placebo-controlled,
      parallel-arm treatment duration of 26 weeks. Treatment effects are assessed by change in a
      combined global outcome when comparing treatment to placebo.
    
  